For relapsing-remitting multiple sclerosis specifically, IFN-β treatment has been a first-line, disease-modifying therapy for over two decades due to its long-term safety profile and therapeutic efficacy (12–14). This evidence concerns the gene IFNB1 and relapsing-remitting multiple sclerosis.